RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT03584464

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Not applicable
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03584464
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, France, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03584464. Allocation not applicable; no masking; primary purpose other. Start 2018-05-14 (actual); primary completion 2020-11-04 (actual). Results posted on 2022-01-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
Intervention (Device)
Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Lead sponsor
Medtronic Vascular (class: industry)

Record details

Record id
cardio:ct-nct03584464
Content hash
927dd6add08991a5d55890a34d779c8806b1edb884ec20b122546ffacc7c4b59